The short answer
Boston Scientific is HALAL in ZakatInvest's qualitative classification, and its current asset-based financial ratios pass the examined methods. Cardiovascular, electrophysiology, endoscopy, urology and neuromodulation devices generally treat disease and preserve life. Product materials, clinical use, access and acquisition exposure still require continuing review.
This is a reproducible research screen, not a fatwa or investment recommendation. A reader should apply the principles of their school and consult a qualified scholar for a binding ruling.
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-13.
11,029 / 44,351
1,453 / 44,351
4,480 / 44,351
- Financial
- Incomplete
- Overall
- Incomplete
Debt is 24.87%, liquidity is 3.28% and receivables plus cash are 10.10%; the examined asset ratios pass, but the FTSE income comparison is incomplete because gross interest income is unavailable.
- Financial
- Pass
- Overall
- Incomplete
Debt is 24.87%, liquidity is 3.28% and receivables plus cash are 10.10%, below the examined MSCI total-assets limits. This is a calculation against the named method, not an index-membership claim.
- Financial
- Pass
- Overall
- Incomplete
Debt is 24.87% and liquidity is 3.28%, below the examined Malaysia SAC financial limits. This is a calculation against SAC ratios, not an official classification of a U.S.-listed security.
- Financial
- Not calculated
- Overall
- Not calculated
A properly licensed and reproducible historical market-cap series is not stored, so these methods are not estimated from a current spot price.
Business-activity disclosure
Boston Scientific develops and manufactures medical devices for cardiovascular, electrophysiology, endoscopy, urology, neuromodulation and related procedures. Medical devices that treat disease and preserve life are generally permissible, while product-specific materials, clinical use, pricing and acquisition exposures require continuing review.
Limitation: The filing does not allocate revenue by product material, procedure, end use, customer contract or downstream clinical application into a universal prohibited-revenue numerator; no blanket zero-concern claim is made.
Purification
Boston Scientific does not separately disclose gross interest income in the examined filing and does not prescribe a scholar-approved purification percentage. Readers should follow the qualified scholar or methodology they use rather than applying the old unsupported 0.5% estimate.
Inputs, assumptions and primary sources
- Inputs use Boston Scientific's March 31, 2026 Form 10-Q; amounts are USD millions as presented in the filing.
- Debt uses $41 million of current debt obligations plus $10,988 million of long-term debt. Finance leases are not entered as conventional debt.
- Cash uses $1,453 million of cash and cash equivalents. The filing identifies money-market funds and time deposits within cash and other current assets; no separately reported fixed-income securities balance is added to avoid double counting.
- Receivables use $3,027 million of trade accounts receivable, net. Factored receivables derecognized from the balance sheet are not added.
- Quarterly net sales are $5,203 million. The filing reports other, net of $151 million but does not separately disclose gross interest income, so no income percentage is estimated.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Current quantitative screen
The calculations use Boston Scientific's official filing at the SEC (Q1 2026 Form 10-Q). Amounts are in USD millions and use total assets as the denominator.
- Interest-bearing debt / assets: 24.87%, using current debt obligations and long-term debt.
- Cash / assets: 3.28%, using reported cash and cash equivalents. No separately identified fixed-income securities are added.
- Receivables plus cash / assets: 10.10%, using trade accounts receivable and cash.
- Disclosed interest income / revenue: unavailable. The filing reports a mixed other-net line rather than a separately isolated gross-interest numerator.
The examined FTSE, MSCI and Malaysia total-assets financial ratios pass. Market-cap denominator methods are not calculated because ZakatInvest does not store a licensed, reproducible historical market-cap series.
What Boston Scientific does
Boston Scientific develops and manufactures medical devices across cardiovascular, electrophysiology, endoscopy, urology, neuromodulation and related procedures. The filing reports $5,203 million of first-quarter net sales and describes a global device business serving physicians and patients.
Medical technology that treats disease, reduces suffering and preserves life is generally permissible commerce and aligns with the maqasid principle of preservation of life. The filing does not allocate revenue by product material, procedure, clinical use or customer contract into a prohibited-revenue numerator, so the qualitative conclusion is transparent rather than an invented zero-concern percentage.
Debt, investments and mixed income
At March 31, 2026, Boston Scientific reported $44,351 million of assets, $1,453 million of cash and cash equivalents, $3,027 million of trade accounts receivable, and $11,029 million of current plus long-term debt. It also entered into acquisition and financing arrangements that can change leverage as transactions close.
The filing reports $151 million of other, net, but does not separately disclose gross interest income. We therefore do not repeat the old unsupported 0.5% claim or prescribe a universal purification amount. Readers should follow their qualified scholar or methodology.
Qualitative considerations
- Biological materials: some devices may use animal-derived or other biological materials. Necessity, transformation and product-specific treatment should be reviewed with a qualified scholar.
- Clinical ethics: safety, informed consent, recalls, evidence, access and pricing remain relevant Islamic-ethics questions.
- Acquisitions: Penumbra and other acquisition activity can change debt, goodwill, product mix and contingent consideration.
- Healthcare procurement: reimbursement, government contracts and global regulatory relationships require continuing review.
- Operations: manufacturing, labor, environmental obligations, intellectual property and supply-chain resilience remain material diligence topics.
The halal verdict
Boston Scientific remains HALAL in ZakatInvest's qualitative classification, with the current examined financial ratios passing while gross interest-income treatment remains unavailable. This is not an official index membership or fatwa. Revisit the record when Boston Scientific files new statements or materially changes its debt, acquisitions, products or biological-material disclosures.
Use the quantitative screen alongside your school's principles and consult a qualified scholar before investing.
Check another asset →